Peptide Stacking Guide
Safer Decision Rules
Most peptide combinations lack robust human evidence. If you combine products, use one change at a time, follow the label, and review the plan with a clinician.
What Stacking Should Mean
Stacking should mean a clinician-reviewed combination with a clear rationale and a way to measure both benefit and harm.
If the combination has not been studied together, assume compatibility, stability, and additive risk are unknown until a prescriber or the product label says otherwise.
Rules That Lower Risk
Change One Variable At A Time
If you add multiple compounds together, you lose the ability to tell what helped or hurt.
Follow The Product Label
The label and dispensing instructions are the safest source for dosing, administration, and storage.
Do Not Mix Unless Allowed
Never assume two products are compatible in the same syringe or vial unless the instructions explicitly say so.
Document Side Effects Early
Log symptoms, timing, and dose changes so you can bring a clean record to a clinician if anything changes.
What This Page Does Not Claim
This page does not present internet stack ideas such as BPC-157 plus TB-500 or CJC-1295 plus Ipamorelin as proven clinical combinations. For most research peptides, human evidence is limited and compatibility data are sparse.
If a prescribed medicine is being combined with anything else, confirm the plan with the prescriber first.
How We Track Safer Experiments
When people do combine products under supervision, the cleanest approach is to log one change, watch for effect, and only then decide whether a second change is worth making.
Shotlee helps keep that record organized by dose, timing, site, and side effects so you can actually compare one phase against the next instead of guessing.
Guide FAQs
Ask whether each component has evidence on its own and in combination. If you cannot find that evidence, treat the compatibility as unknown and proceed only with clinician guidance.
Only if the product instructions or prescriber explicitly say the combination is compatible. Otherwise, keep them separate.
References
- [1]GuidelineFDA Import Alert 66-80. Unapproved GLP-1 drug products and compounding concerns.
- [2]FDAOZEMPIC (semaglutide) prescribing information. U.S. Food and Drug Administration.
- [3]FDAWEGOVY (semaglutide) prescribing information. U.S. Food and Drug Administration.
- [4]FDAMOUNJARO (tirzepatide) prescribing information. U.S. Food and Drug Administration.
Track Your Protocol One Variable At A Time
Keep dose logs, side effects, and timing notes organized in Shotlee.
🚀 Use Shotlee for Free